The gene sequencing giant failed to show that disclosing redacted information would do Illumina any meaningful damage, such as by harming its competitive standing or undermining settlement negotiations, a Delaware judge said in a 14-page ruling. The lawsuit targets the company’s current and former directors.
“To shield the information for which continued confidential treatment is sought from the public and the Fourth Estate, the company must demonstrate a ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.